Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.

Bullboard (TSX:TRIL)

View:
Post by Cider6000on Jul 30, 2020 1:21pm

Manipulated Share Grab this Morning

Someone wants in bad enough that they set up an expensive share grab this morning.  A 7.94 open.. WTF.   the bounce back was fast.  Telling. Let's roll up to 13 again.
Comment by chrispion Jun 30, 2020 9:44am

RE:another interesting Canadian biotech for your consideration

Well that was much quicker than I anticipated. They actually got a business development deal yesterday https://www.businesswire.com/news/home/20200629005790/en/ To put yesterday’s deal  ...more  
Post by chrispion Jun 25, 2020 10:45pm

another interesting Canadian biotech for your consideration

I’ve taken a starter, spec position in Bioasis Technologies (TSX-V: BTI, OTCQB: BIOAF). Others may want to take a look at this in the very near term as it’s a small biotech with a very ...more  
Comment by CleverInvestor2on May 29, 2020 7:51pm

RE:RE:RE:RE:RE:Buy Out

Buyout is a possibility but doubt it'll happen this year. In the meantime, I'm expecting this stock to keep climbing. Next week will be a good week for us.
Comment by birch1on May 29, 2020 9:03am

RE:RE:RE:Buy Out

BOOM BOOM today
Comment by Cider6000on May 22, 2020 3:31pm

RE:Buy Out

Back around early to mid Feb., a company very similar to Trillium was bought out for $5 Billion by a larger pharmaceutical company. I forgot the names, should be some news release during those dates.
Post by SouthernTierTomon May 19, 2020 12:18pm

R&D at 4M ....did they lose 70M in the Q?

and the stock is up $2.00 CAD today? Another Canadien bio-miracle.
Comment by Cider6000on May 18, 2020 6:12pm

RE:RE:RE:RE:RE:RE:RE:RE:Quarterly Report

Yup.  $10 CAN tomorrow or wed. latest.
Comment by birch1on May 18, 2020 5:11pm

RE:RE:RE:RE:RE:RE:RE:Quarterly Report

guess is it will be bought out at 3 plus times current trading and on the TSX, if the numbers hold over night and into tomorrow, we'll trade above $10 per share.
Comment by birch1on May 18, 2020 4:08pm

RE:RE:RE:RE:RE:Quarterly Report

Closed over $7 us today.  would be nice to see this fly, but I'm waiting for the 29th and 30th and buyout.  The numbers will be big.
Comment by birch1on May 18, 2020 2:23pm

RE:RE:RE:RE:Quarterly Report

they are talking about it on stocktwits.
Comment by CleverInvestor2on May 18, 2020 12:00pm

RE:RE:RE:Quarterly Report

Do you have a link for this? That'd be great news. I saw their recent quarter report and they confirmed my intitial thoughts of having enough cash to last them into 2022... and by than we'll ...more  
Comment by Cider6000on May 18, 2020 10:42am

RE:RE:RE:Quarterly Report

 CAN markets Closed today  TRIL @ $6.25 USD.... $8.75 CAN this morning.  Ya Baby
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities